DAF, Human Antibody from MYBIOSOURCE INC.
Search, find, compare suppliers for anti-DAF, Human antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | DAF, Human |
| Clone | 1C6 |
| Host Species | Mouse |
| Reactive Species | human |
| Isotype | IgG1 |
| Format | unconjugated |
| Size | 0.1 mg |
| Concentration | n/a |
| Applications | Flow Ctometry (FC/FACS), Functional Studies (FS), Immuno Assay (IA), Western Blot (WB) |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | The monoclonal antibody 1C6 recognizes human complement decay-accelerating factor (DAF), also designated as CD55. Cells express on their surface several proteins which protect against complement attack, namely complement receptor I (CR1), decay-accelerating factor (DAF), membrane cofactor protein (MCP) and CD59. CR1, DAF and MCP regulate the activation pathways of complement by either accelerating decay of the C3 and C5 convertase (CR1, DAF), or acting as cofactors for the serine protease factor I, which cleaves and irreversibly inactivates C3b (CR1, MCP). Human DAF (CD55) is a protein of 381 amino acids resulting in a ~ 60 kDa transmembrane protein that binds C3b and C4b to inhibit formation and half-life of the C3 convertases. It be |
| Immunogen | Immunogen: Purified DAF from pooled human erythrocyte stroma |
| Other Names | n/a |
| Gene, Accession # | [DAF] |
| Catalog # | MBS584669 |
| Price | $555 |
| Order / More Info | DAF, Human Antibody from MYBIOSOURCE INC. |
| Product Specific References | 1. Fujita, T et al; The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb. J Exp Med 1987, 166: 1221. 2. Higuchi, M et al; Identification of the decay-accelerating factor CD55 as a peanut agglutinin-binding protein and its alteration in non-small cell lung cancers. Clin Cancer Res 2006, 12: 6367 3. Xu, H et al; Investigation of cynomolgus monkey complement. Transplantation Proceedings 2008, 40: 607 4. Okura, E et al; Differential human serum-mediated neutralization of PERV released from pig cells transfected with variants of hDAF. Xenoptransplantation 2008, 15: 365 |
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166
sales@mybiosource.com
http://www.MyBioSource.com
Profile of MYBIOSOURCE INC.
Return to Antibodies